O. Dormond

Discipline

Psychologie (3) Anthropologie biologique (2) Histoire, Philosophie et Sociologie des sciences (1)

Type de document

Articles (38) Recensions (13) Colloques et conférences (1)

Co-auteur

Date

Source

Mot-clé

Cancer (24) Treatment (22) Cells (20) cancer (19) Cancer (19) analyse (14) Inhibitors (14) Human beings (14) Analysis (14) Patients (12) Patients (12) thérapie (11) Therapeutics (11) maladie (10) Example (10) résistance (10) maladie (10) spectacle (9) effet (9) Inhibition (9) Rapamycin (9) modèle (8) ligne (8) Mice (8) Animals (8) Models (8) survie (7) Control (7) Tumors (7) Survival (7)

Documents écrit par O. Dormond (39) | parle de O. Dormond (0)

Basic Science with Preclinical Models to Investigate and Develop Liquid Biopsy: What Are the Available Data and Is It a Fruitful Approach?
B. Cena et al. (10 mai 2022)
Is liquid biopsy the future commutator of decision-making in liver transplantation for hepatocellular carcinoma?
S. Gonvers et al. (2022)
Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma.
M. Rausch et al. (6 août 2021)
Correlation Between Portal Pressure and Indocyanine Green Retention Rate is Unaffected by the Cause of Cirrhosis: A Prospective Study.
K. Kobayashi et al.
Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells.
M. Rausch et al. (16 juin 2021)
Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Clone-Dependent Release of Circulating Tumor DNA.
I. Labgaa et al.
Characterization of Renal Cell Carcinoma Heterotypic 3D Co-Cultures with Immune Cell Subsets.
M. Rausch et al. (22 mai 2021)
Molécules chaperons : exemple de la maladie de Fabry [Chaperone molecules: The example of Fabry disease]
F. Barbey et al.
Combining mTOR Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment.
A. El Hage et al. (17 mars 2021)
The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication.
I. Labgaa et al. (6 févr. 2021)
Hypertrophie ventriculaire gauche isolée : et si c’était une maladie de Fabry ? [Isolated left ventricular hypertrophy : is it a Fabry disease?]
F. Barbey et al. (7 oct. 2020)
Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment.
J.R. van Beijnum et al. (21 sept. 2020)
CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma.
A. Zheng et al. (17 déc. 2019)
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells.
B. Mastelic-Gavillet et al. (10 oct. 2019)
Diclofenac Potentiates Sorafenib-Based Treatments of Hepatocellular Carcinoma by Enhancing Oxidative Stress.
A.P. Duval et al. (27 sept. 2019)
Rebound pathway overactivation by cancer cells following discontinuation of PI3K or mTOR inhibition promotes cancer cell growth.
S. Faes et al. (4 juin 2019)
mTOR in Human Diseases.
O. Dormond (11 mai 2019)
Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma.
M. Zoetemelk et al. (8 mai 2019)
mTOR and Tumor Cachexia.
A.P. Duval et al. (30 juil. 2018)
Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.
S. Faes et al. (1 nov. 2017)
Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer.
E. Uldry et al. (30 juin 2017)
Ascending aortic remodelling in Fabry disease after long-term enzyme replacement therapy.
P. Monney et al. (2017)
Long-term follow-up of pulmonary function in Fabry disease: A bi-center observational study.
D.P. Franzen et al. (2017)
Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity.
S. Faes et al. (2017)
Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies.
S. Faes et al. (27 déc. 2016)

next